Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Tropical spastic paraparesis is a chronic systemic immune-mediated inflammatory myeloneuropathy, more frequently reported in women than in men, that usually presents in adulthood with slowly progressive spastic paraparesis of the lower limbs, bladder and bowel dysfunction, and sensory disturbances in the lower extremities (e.g. paresthesia and dysesthesia) and that is associated with a human T-cell lymphotropic virus type 1 (HTLV-1) infection.
Features include: Myelopathy, Abnormal pyramidal sign, and Spastic paraparesis.
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Phenotype Count |
|---|
Example Features |
|---|
Brain and nerves | 2 | Myelopathy, Spastic paraparesis |
Biomarker and diagnostic research for tropical spastic paraparesis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
118 publications have been identified in PubMed for tropical spastic paraparesis. Research spans Basic Science / Preclinical (31%), Review / Meta-Analysis (26%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 37 | 31% |
Research summaries | 31 | 26% |
Disease patterns and progression | 20 | 17% |
Testing and diagnosis research | 9 | 8% |
Patient case studies | 9 | 8% |
Clinical study results | 6 | 5% |
New treatment approaches | 4 | 3% |
Other research | 2 | 2% |
Siyadat P (2026). [PMID: 42246505](https://pubmed.ncbi.nlm.nih.gov/42246505/). *J Med Virol*. [Basic Science / Preclinical]
Prakash R (2026). [PMID: 41760966](https://pubmed.ncbi.nlm.nih.gov/41760966/). *Neurol Sci*. [Case Report / Case Series]
Morrison AA (2026). [PMID: 41894649](https://pubmed.ncbi.nlm.nih.gov/41894649/). *Neurol Neuroimmunol Neuroinflamm*. [Review / Meta-Analysis]
Neves ES (2026). [PMID: 41717922](https://pubmed.ncbi.nlm.nih.gov/41717922/). *J Med Virol*. [Epidemiology / Natural History]
Noori B (2026). [PMID: 41737026](https://pubmed.ncbi.nlm.nih.gov/41737026/). *Can J Infect Dis Med Microbiol*. [Review / Meta-Analysis]
Letafati A (2026). [PMID: 41714539](https://pubmed.ncbi.nlm.nih.gov/41714539/). *J Neurovirol*. [Review / Meta-Analysis]
Fernandes LA (2026). [PMID: 41751961](https://pubmed.ncbi.nlm.nih.gov/41751961/). *Int J Mol Sci*. [Basic Science / Preclinical]
Kamate DP (2026). [PMID: 42031371](https://pubmed.ncbi.nlm.nih.gov/42031371/). *BMJ Case Rep*. [Case Report / Case Series]
Blanco S (2026). [PMID: 41242568](https://pubmed.ncbi.nlm.nih.gov/41242568/). *Microb Pathog*. [Epidemiology / Natural History]
Forouzanfar ES (2026). [PMID: 32809660](https://pubmed.ncbi.nlm.nih.gov/32809660/). *Unknown Journal*. [Basic Science / Preclinical]
AI-curated news mentioning tropical spastic paraparesis
Updated Aug 24, 2026
A case report details an adolescent with ovarian lymphoma and bone metastasis presenting with paraparesis. This study contributes to the understanding of rare presentations of lymphoma in young patients.
A case report details acute myocardial infarction in a patient with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), highlighting circulatory dynamics during mobilization before and after antihypertensive drug modification. This study contributes to understanding cardiovascular risks in patients with HAM/TSP.
A 10-year analysis from the Japanese HAM-net registry demonstrates the effectiveness of the 10-meter timed walk as a monitoring tool for long-term gait progression in patients with human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis. This study provides valuable insights into disease progression metrics.